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Summary
T helper 9 (Th9) cells and interleukin (IL)-9 are involved in the
pathogenesis of several autoimmune diseases. The exact role of IL-9 and
Th9 cells in patients with systemic sclerosis (SSc) have not yet been studied
adequately. IL-9, IL-9R, transcription factor PU.1 (PU.1), IL-4, thymic
stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-b
expression were assessed in skin and kidney biopsies of SSc patients and
healthy controls (HC) by immunohistochemistry (IHC). The cellular source
of IL-9 was also analysed by confocal microscopy analysis. Peripheral IL-9-
producing cells were also studied by flow cytometry. The functional
relevance of IL-9 increased expression in SSc was also investigated. Our
results demonstrated a strong expression of IL-9, IL-9R, IL-4, TSLP and
TGF-b in skin tissues of patients with both limited and diffuse SSc. IL-9
expression was observed mainly in the context of skin infiltrating
mononuclear cells and keratinizing squamous epithelium. IL-9 over-
expression was also observed in renal biopsies of patients with SSc. IL-9
producing cells in the skin were identified as Th9 cells. Similarly, Th9 cells
were expanded and were the major source of IL-9 among SSc peripheral
blood mononuclear cells (PBMC), their percentage being correlated directly
with the modified Rodnan skin score. Infiltrating mononuclear cells, mast
cells and neutrophils expressed IL-9R. In in-vitro studies stimulation with
rIL-9 significantly induced NET (neutrophil extracellular traps) release by
dying cells (NETosis) in neutrophils, expansion of mast cells and increase of
anti-systemic scleroderma 70 (Scl70) production by B cells. Our findings
suggest that Th9 cells and IL-9 could be implicated in the pathogenesis of
SSc.
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Introduction
Systemic sclerosis (SSc) is a chronic autoimmune disorder
in which abnormal immune responses lead to activation
and expansion of autoreactive effector immune cells,
resulting in fibrosis of multiple organs [1]. Accumulating
data suggest that infiltrating CD41 T helper (Th) cells,
essentially skewed towards Th2 and Th17 phenotypes, play
important roles in essentially mediating inflammation and
fibrosis progression [1,2].
Recently, interleukin (IL)-9, a pleiotropic cytokine pro-
duced mainly by Th9 cells, has been demonstrated to par-
ticipate actively in the induction of tissue fibrosis and in
the pathogenesis of different autoimmune disorders [3,4].
The differentiation of Th9 cells requires a balance of sig-
nals, including IL-4 and transforming growth factor
(TGF)-b [5], and the epithelial cytokine thymic stromal
lymphopoietin (TSLP) [6], resulting in the induction of
the transcriptional factor PU.1 that, in concert with inter-
feron (IFN) regulatory factor 4 (IRF4), directly binds the
IL-9 promoter and activates gene expression in Th9 cells
[7]. Once differentiated, Th9 cells require activation of the
IL-25/IL–17RB axis to produce high levels of IL-9 [8,9]
Increased expression of Th9 polarizing cytokines and of
IL-25 has been demonstrated previously in patients with
SSc [10–12], but the expression of IL-9 and Th9 cells has
not yet been studied adequately. In the present study, we
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analysed the expression of IL-9 and Th9 cells in SSc. We
further examined the relationship of Th9 cells with specific
subsets of SSc and the expression of Th9 relevant cytokines,
including IL-17A, TGF-b1, TSLP and IL-4 and the role of
IL-9 in modulating the function of IL-9R-expressing cells.
The aim of the study was to evaluate Th9/IL-9 expression
in different tissues of SSc patients as a possible player in the
pathogenesis of SSc, thus representing a potential therapeu-
tic target.
Patients and methods
Skin biopsy specimens of sclerotic cutis and peripheral
blood were obtained after informed consent from 20
patients with SSc diagnosed according to the 2013 classifi-
cation criteria for systemic sclerosis [13] (13 patients with
limited and seven with diffuse SSc) (18 female and
two male, mean age 5 42 6 12 years, mean disease
duration 5 34 6 12 months) and 20 healthy controls (age-
and sex-matched) who underwent surgery for non-
cutaneous disease evaluation. Kidney samples were also
obtained from an additional eight patients with SSc in
whom renal biopsy was performed for hypertensive renal
crisis attributable to SSc or persistent renal impairment
(serum creatinine value > 2 mg/dl plus a diastolic blood
pressure > 110 mmHg), or otherwise inexplicable presence
of blood and/or protein in the urine. Renal biopsies were
also obtained from five controls with isolated urinary
alterations but normal kidney histology. Modified Rodnan
skin score was calculated to assess the extension of skin
involvement [14]. Pulmonary involvement was defined as a
forced vital capacity < 70% of predicted, as measured by a
dry spirometer, or by the evidence of amorphous or reticu-
lonodular infiltrates in high-resolution computed tomog-
raphy scans (HRCT). Pulmonary hypertension (PH) was
also evaluated [pulmonary artery pressures (PAPs) > 25
mmHg and peak tricuspid regurgitant jet velocity (TRV)
>27 m/s] according to Denton et al. [15]. Table 1 shows the
baseline characteristics of the patients. Age- and sex-
matched healthy donors (HD) were enrolled as controls.
Collection of samples was approved by the ethical commit-
tee and the Institutional Review Board of the University of
Palermo and informed consent was obtained from each
patient and controls in accordance with the Helsinki
Declaration.
Immunohistochemistry
Tissue samples were fixed immediately with 4% formalde-
hyde and embedded in paraffin. Immunohistochemistry
analysis was performed on 5-lm-thick paraffin-embedded
sections. Following rehydration, antigen was unmasked for
45 min at 958C using Dako Target retrieval solution (pH
6.0) (Dako, Glostrup, Denmark). Endogenous peroxidase
was blocked for 10 min with Dako peroxidase blocking
reagent, and non-specific binding was blocked for 20 min
Table 1. Baseline characteristics
Patients
Limited versus
diffuse SSc
Modified Rodnan
skin score
Pulmonary
involvement
Pulmonary
hypertension Autoantibodies %Th9
1 Limited 18 Yes Yes Scl-70 072
2 Diffuse 27 Yes None Scl-70 089
3 Diffuse 24 None None ANA 092
4 Diffuse 33 Yes None Scl-70 1
5 Limited 15 None None ANA 069
6 Diffuse 23 None None ANA 076
7 Limited 24 None Yes ACA 060
8 Limited 12 None Yes ACA 081
9 Limited 9 None Yes ANA 073
10 Limited 16 None Yes ACA 1
11 Diffuse 38 Yes None Scl-70 087
12 Limited 12 Yes None ANA 060
13 Limited 15 Yes None ANA 079
14 Diffuse 19 Yes None Scl-70 088
15 Limited 22 None Yes ANA 062
16 Limited 26 Yes None ANA 067
17 Limited 12 None None ACA 066
18 Limited 14 Yes None ANA 072
19 Limited 28 Yes None ANA 078
20 Diffuse 26 None None ACA 085
Controls (mean 6 s.e.m.) – – – – – 02040 6 005384
Patients (mean 6 s.e.m.) – – – – 07780 6 002751
SSc 5 systemic sclerosis; Th9 5 T helper type 9; s.e.m. 5 standard error of the mean.
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with Dako protein block. The primary antibodies were
added and incubated for 1 h at room temperature.
Isotype-matched irrelevant antibodies were used as a nega-
tive control [mouse immunoglobulin (Ig)G1 monoclonal
antibody (mAb) (ab27479) and rabbit IgG polyclonal
antibody (ab27472); Abcam, Cambridge, UK)]. Following
three washes with Tris-buffered saline, slides were incu-
bated for 30 min with peroxidase-conjugated Dako EnVi-
sion polymer. After three further washings, peroxidase
activity was visualized using diaminobenzidine chromogen
(Dako), and slides were counterstained lightly with hae-
matoxylin before dehydration and mounting in DePex
(VWR International, Radnor, PA, USA). Sections were
analysed by two experienced scientists (A. R., F. C.) who
were blinded with regard to subject group. The number of
positive cells was determined by counting immunoreactive
cells on photomicrographs obtained from three randomly
obtained high-power microscopic fields (3400 magnifica-
tion) under a DM2000 optical microscope, using a
DFC320 digital camera (Leica, Wetzlar, Germany). To
address specifically the nature of IL-9-producing cells, tri-
ple staining for Th17 and Th9 cells were performed on
paraffin-embedded skin sections. Sections were treated
with fluorescein isothiocyanate (FITC)-, Rhodamine
Redor Cy-5-conjugated anti-mouse or anti-rabbit antibod-
ies (Invitrogen, Carlsbad, CA, USA) plus RNasi (200 ng/
ml) and counterstained using (40,6-diamidino-2-phenylin-
dole (DAPI; Life Technologies, Paisley, UK]. Confocal
analysis was used to acquire fluorescence staining. A list of
the antibodies used is shown in Supporting information,
Table S1.
Isolation of peripheral blood mononuclear cells and
flow cytometry
Peripheral blood mononuclear cells (PBMC) were obtained
by density gradient centrifugation using Ficoll-Hypaque
(Pharmacia Biotech, Uppsala, Sweden) and were cultured
in RPMI-1640 supplemented with 10% fetal calf serum
(FCS) and antibiotics from 15 SSc patients (10 with limited
SSc and five with diffuse SSc) and 10 healthy controls. Cell
viability (trypan blue dye exclusion) was always > 95%.
Cells were activated with anti-CD3/CD28 beads (ratio
1 : 2) for 6 h and then stained with mAb. Flow cytometry
analysis was performed using a FACSCanto (BD Bioscien-
ces). At least 50 000 cells (events), gated on lymphocyte
region, were acquired for each sample. Data were analysed
with FlowJo software programs (FloJo, TreeStar Inc., Ash-
land, OR, USA). A list of the antibodies used is listed in
Supporting information Table S1.
Cell cultures
Mast cells and B cells were isolated with microbeads (anti-
CD117 and CD19, respectively) (positive selection) and
magnetic-activated cell sorting techniques (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions. Neutrophils were isolated from
peripheral blood using the density gradient separation
method with a mixture of sodium metrizoate and dextran
500 and lysis of residual erythrocytes. Cells were cultured in
24-well flat-bottomed plates (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) at a density of 1 3 106 cells in
1 ml of RPMI-1640 medium with 10% FCS, 2 mM L-
glutamine, 20 nM HEPES and 100 U/ml penicillin/strepto-
mycin with or without recombinant IL-9 (rIL-9) (10 ng/ml)
(R&D Systems, Minneapolis, MN, USA). Cells were incu-
bated at 378C in a humidified atmosphere containing 5%
CO2 for 48 h. After incubation cells were fixed, stained with
myeloperoxidase (MPO) and counterstained with DAPI.
Confocal analysis was used to acquire fluorescence staining.
Statistical analysis
Student’s t-test or the non-parametric Mann–Whitney U-
test was used to calculate the statistical significance between
groups. P-values less than 005 were considered significant.
Results
IL-9 is up-regulated in skin specimens of SSc patients
We first investigated whether IL-9 was up-regulated in skin
specimens of SSc patients. As shown in Fig. 1, IL-9 expres-
sion was increased in both diffuse and limited SSc patients.
In particular, IL-9 expression was detected mainly between
infiltrating cells, endothelial cells and keratinizing squamous
epithelial cells of skin of SSc subjects (Fig. 1a–c,l). The cellu-
lar source of IL-9 was represented prevalently by Th9 cells,
as demonstrated by the co-localization of IL-9 and the tran-
scriptional factor PU.1 (Fig. 1e–h). IL-9-producing Th17
cells were also found in the skin specimens of SSc patients
(Fig. 1e–h). According to IL-9 over-expression, IL-9R was
expressed intensely among infiltrating cells and keratinizing
squamous epithelial cells (Fig. 1i–k,m). With regard to the
expansion of Th9 cells, we next evaluated the expression of
Th9-inducing cytokines in skin specimens of SSc. As shown
in Fig. 2a–i, increased expression of IL-4, TSLP and TGF-b
was detected in in skin tissues of patients with SSc, especially
in those with diffuse disease.
The IL-25–IL-17RB pathway has been demonstrated to
be important in the induction of IL-9 production by Th9
cells [9]. As shown in Fig. 2l–s, we found over-expression
of IL-25, IL-17RB and of the specific tumour necrosis fac-
tor (TNF) receptor-associated factor 6 (TRAF6) in the skin
of SSc patients compared to controls. IL-9 over-expression
was also observed in the inflamed glomeruli obtained
from SSc patients (Supporting information, Fig. S1). In
particular, SSc patients displayed intense staining in the
context of mesangial glomerular cells with weak tubular
epithelial cells positivity (Supporting information, Fig. S1).
G. Guggino et al.
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Conversely, HC showed intense tubular epithelial cell posi-
tivity (Supporting information, Fig. S1). These findings
indicate that the Th9 pathway is activated strongly in SSc
patients.
Phenotypical analysis of IL-9-producing cells among
PBMC of SSc patients
The expression of IL-9 by different subsets of T helper cells
was also analysed by FACS analysis on cells isolated from
Fig. 2. Interleukin (IL)-4, transforming growth factor (TGF)-b, thymic stromal lymphopoietin (TSLP), IL-25, IL-17RB and tumour necrosis
factor (TNF) receptor associated factor 6 (TRAF6) expression in systemic sclerosis (SSc) and healthy donors (HD). IL-4, TGF-b, TSLP, IL-25,
IL-17RB and TRAF6 expression in the skin of SSc patients (b,e,h,m,p,s) and controls (a,d,g,l,o,r). Quantification of IL-4-, TGF-b–, TSLP-, IL-25-,
IL-17RB- and TRAF6-producing cells from SSc patients and controls (c,f,i,n,q,t). Original magnification 3250. Data are expressed as
mean 6 standard error of the mean (s.e.m.); *P< 005. [Colour figure can be viewed at wileyonlinelibrary.com]
Fig. 1. Interleukin (IL)-9 and IL-9R expression in the skin of systemic sclerosis (SSc) and HD. IL-9 expression in the skin of SSc patients (a–c)
and controls (d). Single staining for IL-9 (e), IL-17 (f) and transcription factor PU.1 (PU.1) (g). (h) Merged triple staining for IL-9, IL-17 and
PU.1 in the skin of SSc patients. IL-9R expression in the skin of SSc patients (i,k) and controls (j). Quantification of IL-9 and IL-9R-producing
cells from SSc patients and controls (l,m). Original magnification 3400 (i), 3250 (a,b,d,j,k), 3630 (c). Data are expressed as mean 6 standard
error of the mean (s.e.m.); *P< 005. [Colour figure can be viewed at wileyonlinelibrary.com]
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the peripheral blood of patients with SSc and controls. As
shown in Fig. 3, IL-9-producing CD41 T cells from
patients with SSc were expanded significantly compared to
control subjects. Among CD41 T cells, the percentage of
IL-9-producing Th9 (076 002 versus 026 005) (Fig.
3a,c) and Th17 (126 03 versus 0336 008) (Fig. 3d) cells
was significantly higher in SSc patients respect to controls.
Conversely, the percentage of IL-9-producing Th2
(046 009 versus 026 003) cells was not significantly dif-
ferent in the two groups (Fig. 3b). Interestingly, frequencies
of Th9 cells were significantly higher in patients with dif-
fuse SSc and the number of IL-9-expressing cells was corre-
lated significantly with the modified Rodnan skin score,
but not with pulmonary hypertension (Fig. 3e–g). These
findings indicate the presence of a Th9 polarization in the
peripheral blood of SSc patients.
Innate lymphoid cells type 2 (ILC2) are expanded in
the skin and peripheral blood of SSc
Th9-derived IL-9 has been demonstrated to activate ILC2
in a mast cell-dependent manner [16]. Furthermore, ILC2
have been described to be expanded in SSc patients [17].
Thus, we next evaluated the frequencies of Th2 polarized
ILC2 subsets in the skin and peripheral blood of SSc
patients (Fig. 4). According to a previous report, ILC2 were
expanded significantly in peripheral blood (Fig. 4a,b), and
cells resembling the ILC2 phenotype were also increased in
the skin (Fig. 4c) of SSc patients compared to controls. A
significant and direct correlation was also found between
the percentages of circulating ILC2 and Th9 cells (Fig. 4g).
Effect of IL-9 on B cells, mast cells and neutrophils in
SSc
Beyond ILC2, IL-9 receptor is also expressed on neutrophils
and mast cells (MC), which have been involved in the
pathogenesis of SSc [18,19]. We next evaluated, in vitro, the
role of recombinant IL-9 in the modulation of IL-9R-
expressing cells isolated from the peripheral blood of SSc
patients. IL-9 stimulation of neutrophils increased the pro-
duction of IL-8 significantly and neutrophil extracellular
trap pathogen-induced cell death (NETosis) strongly, as
demonstrated in Fig. 5a where the nuclei of neutrophils
lose their shape, and the NETs are released as the cell mem-
brane breaks. Stimulation of MC induces their significant
expansion (Fig. 5b) and stimulation of B cells resulted in a
significantly increased release of SSc-related autoantibodies
(Fig. 5c).
Discussion
In this study we show, for the first time, that the IL-9/IL-
9R axis is up-regulated in the inflamed skin of SSc patients
and is accompanied by the expansion of pathogenic Th9
cells. We also demonstrated that Th9 polarization occurs in
Fig. 3. Percentage of T helper type 9 (Th9), Th17 and Th2 in systemic sclerosis (SSc) and healthy donors (HD). Representative dot-plot analysis
and gating strategy in an SSc patient (a). Percentage of Th2 (b), Th9 (c) and Th17 (d) cells in SSc and HD. Mean percentage of Th9 cells in
patients with diffuse or limited disease (e). Direct correlation of Th9 percentage in SSc and pulmonary hypertension (f) and Rodnan skin score
(g). Data are expressed as mean 6 standard error of the mean (s.e.m.). [Colour figure can be viewed at wileyonlinelibrary.com]
G. Guggino et al.
212 VC 2017 British Society for Immunology, Clinical and Experimental Immunology, 190: 208–216
Fig. 4. Innate lymphoid cells (ILC) type 2 are expanded in systemic sclerosis (SSc) patients. Representative dot-plot analysis and gating strategy
in a SSc patient (a). Mean percentage of ILC2 cells among peripheral blood mononuclear cells (PBMC) of patients and HD (b). Single staining
for chemoattractant receptor Th2 (CRTH2) (c), GATA binding protein 3 (GATA3) (d) and interleukin (IL)-4 (e). (f) Merged triple staining for
CRTH2, GATA3 and IL-4. ILC2 are directly correlated with Th9 (g). Data are expressed as mean 6 standard error of the mean (s.e.m.);
*P< 005. [Colour figure can be viewed at wileyonlinelibrary.com]
Fig. 5. Effect of recombinant interleukin (IL)-9 on neutrophils, mast cells and B lymphocytes. Immunofluorescences for neutrophil extracellular
traps release by dying cells (Netosis): single staining for myeloperoxidase (MPO) in untreated and interleukin (IL)-9 treated neutrophils (a).
Expansion of CD117-positive mast cells after in-vitro culture with recombinant IL-9 (b). Anti-systemic scleroderma 70 (Scl70) production after
in-vitro stimulation of B lymphocytes with recombinant IL-9 (c). [Colour figure can be viewed at wileyonlinelibrary.com]
IL-9 pathway in systemic sclerosis
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inflamed skin and in the peripheral blood of SSc patients,
being correlated directly with the modified Rodnan skin
score but not with pulmonary hypertension. Similar to the
skin, IL-9 expression was also found increased in renal
biopsy specimens of SSc patients with renal crisis. Finally,
in-vitro treatment with rIL-9 was associated with a signifi-
cant induction of NETosis in neutrophils, significantly
increased production of SSc-related autoantibodies by B
lymphocytes and the expansion of MC.
IL-9 is a recently described proinflammatory cytokine
because of its capacity to support proliferation of B and T
cell infiltration [20]. In combination with IL-17, IL-9
increases the accumulation of neutrophils and perpetuates
chronic inflammation [21], as observed in several auto-
immune disorders such as rheumatoid arthritis (RA),
psoriatic arthritis and giant cell arteritis (GCA) [22]. IL-9
production was associated first with the Th2 phenotype,
even if other T helper subsets appear to have the potential
for IL-9 production such as Th17 cells and regulatory T
cells (Treg) [23,24]. More recently, it has been demonstrated
that Th0 can differentiate into a specialized subset of IL-9-
producing T cells, named Th9. Th9 differentiation and IL-9
expression is enhanced by IL-4, TGF-b and TSLP [5,6,25]
and induced by the activation of the ETS-family transcrip-
tion factor PU.1 [7,26]. Increased serum levels of IL-9 have
been found recently in SSc, suggesting that the IL-9 axis
might be involved in SSc pathogenesis [10]. However, no
studies addressing specifically the nature of IL-9-producing
cells and the functional consequences of IL-9 over-expres-
sion have yet been published.
In SSc skin, dermal fibroblasts, inflammatory infiltrating
cells and endothelial cells produced mainly IL-9. In partic-
ular, Th9 cells and, in a lesser manner, Th17 cells were the
major sources of IL-9 in SSc skin. Th9 cells seem to be
involved in the immunopathology of different systemic
rheumatic diseases in which this axis is activated and
involved potentially in the triggering and/or maintaining
inflammation. The differentiation of Th9 cells requires the
activation of IL-2/signal tranducer and activation of
transcription-5 (STAT-5) and IL-4/STAT-6 signalling and
TGF-b that act by inducing redirection of naive T cells
from a Th2 to Th9 cell differentiation pathway [5,27].
Recently, it has been demonstrated that TSLP, IL-25 and
IL-33 may also enhance IL-9 production by Th9 cells [6,9].
According to the expansion of Th9 cells, TGF-b, TSLP and
IL-4 were up-regulated significantly in SSc skin and corre-
lated directly with the expression of IL-9 and the number
of Th9 cells. In addition, the IL-25/IL-17RB pathway was
also activated in SSc patients, as indicated by over-
expression of IL-25, IL-17RB and of the specific transcrip-
tion factor TRAF6 in the skin of SSc patients. Taken
together, these findings seem to point towards a strong
activation of IL-9/Th9 axis in SSc.
A mast cell–ILC2–Th9 pathway has been demonstrated
to be functional in human diseases such as cystic fibrosis
[28]. Although ILC2 expansion has been demonstrated
recently in SSc [17], no studies have been performed on
the functional pathways involved in their activation.
Accordingly, with IL-9 over-expression, we observed a sig-
nificant ILC2 expansion in SSc patients that correlated sig-
nificantly with the percentages of circulating Th9 cells.
Interestingly, ILC2 expansion was also accompanied by the
increased frequencies of both circulating and tissue mast
cells in SSc patients. Finally, isolated mast cells from the
peripheral blood were expanded significantly by the addi-
tion of IL-9 in in-vitro experiments and produced high lev-
els of IL-2, indicating that a mast cell–ILC2–Th9 pathway
is also functional in SSc patients.
The biological effects of IL-9 are mediated by IL-9R, a
heterodimeric receptor composed by a a-chain (IL-9Ra)
and a common g-chain receptor shared by other cytokines.
According to the increased expression of IL-9, IL-9R was
also up-regulated significantly in the inflamed skin of SSc
patients, essentially among infiltrating lymphocytes, mast
cells and neutrophils. In order to study the functional rele-
vance of the increased frequency of IL-9R-expressing cells
in SSc, isolated neutrophils and B cells were stimulated
with recombinant IL-9. IL-9, through interaction with the
cognate IL-9R alpha expressed on human B cells, induces B
cell expansion and activation by activating STAT-3 and
STAT-5 [29]. In our study, in in-vitro studies IL-9 was able
to induce the production of SSc-specific autoantibodies in
isolated SSc B lymphocytes, indicating an important role of
IL-9/IL-9R alpha axis in modulating autoimmunity in SSc
patients [24]. Stimulation of neutrophils with IL-9 induces
NETosis activation. NETs are chromatin structures loaded
with anti-microbial molecules that represent one of the
first lines of defence against pathogens. In vivo, NETs are
released during a form of pathogen-induced cell death,
named NETosis. NETosis activation has been demonstrated
in autoimmune diseases such as RA and systemic lupus
erythematosus but never studied in SSc. Here, we demon-
strated that NETosis is also activated in SSc patients and it
is possibly induced by IL-9. The functional consequence of
NETosis activation in SSc needs to be addressed specifically
in further studies.
Taken together, our results suggest that Th9 cells and
IL-9 could play an important role in the pathogenesis of
SSc by modulating adaptive and innate immune responses
and the production of autoantibodies and indicate the IL-9
pathway as a possible therapeutic target.
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Supporting information
Additional Supporting information may be found in the
online version of this article at the publisher’s web-site:
Table S1. List of antibodies.
Fig. S1. Interleukin (IL)-9 expression in the kidney of
systemic sclerosis (SSc) and healthy donors (HD). IL-9
expression in the kidney of SSc patients with renal crisis
(a) and controls (b). Quantification of IL-9-producing
cells from kidney tissue from SSc patients and controls
(c). Original magnification 3250. Data are expressed as
mean 6 standard error of the mean (s.e.m.); *P< 005.
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